Biogen Inc (BIIB)

227.43
+3.32(+1.48%)
  • Volume:
    238,751
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    223.65 - 227.65

BIIB Overview

Prev. Close
224.11
Day's Range
223.65-227.65
Revenue
11.1B
Open
225.17
52 wk Range
221.72-468.2
EPS
10.22
Volume
238,751
Market Cap
33.16B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,147,373
P/E Ratio
21.93
Beta
0.44
1-Year Change
-8.85%
Shares Outstanding
146,892,712
Next Earnings Date
Jan 27, 2022
What is your sentiment on Biogen Inc?
or
Vote to see community's results!

Biogen Inc Company Profile

Employees
9100

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyNeutralSellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyBuyStrong SellStrong Sell
  • 01708620849
    0
    • is better to buy RTX US defense company . don't risk your money in Biogen .
      0
      • still a good moment to buy?
        4
        • yes
          1
        • is better to buy RTX US defense company . don't risk your money in Biogen .
          2
      • what is going on with this
        1
        • 2021.07.15 - RB Best Buy @$324
          0
          • wow
            0
            • Any action for the price soon
              0
              • Congress is investigating this company and its FDA approval using bribery.
                2
                • https://www.fool.com/investing/2021/06/26/the-upside-for-biogen-is-absolutely-wild/
                  1
                  • i need Bitcoin
                    1
                    • just buy at dip very good price now for long term
                      1
                      • okay how can you get me the Bitcoin
                        1
                      • I buy and sell
                        1
                      • you need a better Bitcoin
                        1
                    • hmmmm..
                      0
                      • If yall believe this should still be at this price level after they botched and ended all their research because of lack of results you belong in a mental hospital
                        2
                        • It is funny how you are ignorant about biogen stock, you must look to the fundamentals and understand the business... what weak conversation
                          2
                          • MONEY ???orsafety
                            1
                            • A new chapter is just open!!
                              0
                              • short position let's go to 320 ;)
                                1
                                • trash
                                  0
                                  • back to reality today, terrace back to 340-350 and then eventually io Who knows.
                                    0
                                    • I'm only shorting this today because I expect some realistic pullback but idk long term
                                      1
                                      • Baddest boeing wad growing even higher than biogen. And on these good news you expecting pullback?)
                                        0
                                    • 300 EOW.
                                      1
                                      • another case of manipulation not evidence educanumab benefits n FDA gets approval
                                        2
                                        • thomthe473@gmali.com
                                          0
                                          • this will collapse soon..the ceo clearly mentioned that he 'is not sure about the successful results of this new development' it will take at least 5-9 years for proper data and confirmation..it's just all amc style jump nothing else.
                                            3
                                            • BIIB $395.85 +38.34% @ Close! FDA OK’s Alzheimer’s Drug Aducanumab.
                                              0
                                              Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                              Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.